Individualizing dual antiplatelet therapy duration: Prediction tools, genomics, and clinical judgment

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacogenomics

Background:

• Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) is standard but carries risks.
• Prolonged DAPT reduces myocardial infarction (MI) risk but elevates major bleeding events.
• Current DAPT duration strategies often represent population averages, not individual patient needs.

Discussion:

• Individualizing DAPT duration using prediction tools, like the DAPT trial's net benefit calculator, can refine risk-benefit profiles.
• Genomic data offers potential for further optimization in agent selection and therapy duration.
• Clinical judgment is crucial for integrating diverse patient-specific factors beyond current predictive models.

Key Insights:

• Personalized DAPT duration can improve net clinical outcomes compared to standard protocols.
• Genomic-guided therapy may enhance the efficacy and safety of antiplatelet treatment.
• A multifaceted approach combining predictive tools, genomics, and clinical expertise is optimal.

Outlook:

• Future research should focus on validating genomic markers for DAPT selection and duration.
• Development of more sophisticated predictive algorithms integrating clinical, genomic, and patient-reported data is warranted.
• Wider clinical adoption of personalized DAPT strategies is expected to improve post-PCI care.